Clinical Evaluation of New Antiarrhythmic Agents PDF Download

Author: Francesco Furlanello
Publisher:
ISBN:
Category :
Languages : en
Pages :

View

Book Description

Author: United States. Food and Drug Administration
Publisher:
ISBN:
Category : Arrhythmia
Languages : en
Pages : 16

View

Book Description

Author: J. Morganroth
Publisher: Springer Science & Business Media
ISBN: 9400982704
Category : Medical
Languages : en
Pages : 324

View

Book Description
Thus, there are now several chronic canine myocardial infarction ventricular tachyarrhythmia models which are available for the evaluation of new antiarrhythmic drugs (Table I). The available models fulfill many, but not all of the requirements for an ideal chronic arrhythmia model (Table 11). The sustained arrhythmias initiated in these models using programmed pacing presumably have the same localized reentrant mechanism that characterizes chronic human myocardial infarction and chronic coronary 26 artery disease. However, these models are not suitable for determining whether a new drug will abolish spontaneous ly-occurring PVCs. In addition, these models are of unproven value in the study of acute spontaneously occurring sudden death; although recently initiated, provocative work may shed further light on this subject. Most importantly, the available models do seem well-suited to the evaluation of new drugs intended for use in chronic coronary artery disease patients at risk for sustained reentrant ventricular tachycardia or VF. Notably, the results of preliminary electropharmacologic studies in these canine models parallel closely those findings reported in human patients with sustained life-threatening ventricu lar tachyarrhythmias (Table Ill). Therefore, increased use of these chronic models for new antiarrhythmic drug testing is strongly recommended. TABLE II Ideal vs Available Chronic Canine - Arrhythmia Models Ideal Available 1. (a) Arrhythmia mechanism comparable to Yes patients with chronic CAD: Reentry (b) Pathophysiology similar (e. g. , atherogenic CAD) No 2. Susceptible to: (a) spontaneous PVCs No l No (b) spontaneous VT/VF (c) inducible VT/VF Yes 3.

Author: Symposium Clinical Evaluation of Response to Antiarrhythmic Therapy (1988, Atlanta, Ga.)
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 49

View

Book Description

Author:
Publisher:
ISBN: 9789024723362
Category : Arrhythmia
Languages : en
Pages : 323

View

Book Description

Author: United States. Food and Drug Administration
Publisher:
ISBN:
Category : Arrhythmia
Languages : en
Pages : 7

View

Book Description

Author: Raymond Woosley
Publisher: CRC Press
ISBN: 9780824781644
Category : Medical
Languages : en
Pages : 0

View

Book Description
This vitally important reference traces the progress of antiarrhythmic drug trials and treatment methods-from the vantage point of the clinicians who designed and conducted the studies to objective views of the strengths and weaknesses of the results, identifying unresolved questions or newly created issues. Reviews significant studies in chronological order-providing a clear, informative account of how current thinking about arrhythmia treatment has evolved. Written by over 35 leading experts in the field, Clinical Trials on the Treatment of Arrhythmias emphasizes the need for science-based therapeutics and rigorously controlled clinical trials of drugs and implantable devices compares electrocardiographic monitoring with electrophysiological techniques for arrhythmia management analyzes the landmark Cardiac Arrhythmia Suppression Trial (CAST) evaluates the effectiveness of amiodarone describes sodium and potassium channel blockers and the development of drugs that slow conduction velocity and prolong repolarization and refractoriness investigates the effects of the d-isomer of sotalol on mortality critiques studies on the established efficacy of implantable devices versus amiodarone to benefit post-bypass surgery patients and more! Containing over 600 literature citations, Clinical Trials on the Treatment of Arrhythmias is an invaluable resource for cardiologists and cardiovascular specialists, pharmacologists, pharmaceutical researchers, and graduate and medical school students in these disciplines.

Author: eRegs & Guides
Publisher: eregs & guides
ISBN:
Category : Business & Economics
Languages : en
Pages : 466

View

Book Description
Good Clinical Practice eRegs & Guides provides a reference to key US FDA Guides and regulations via your electronic reader. An excellent way to access the reference documents on your e-reader. No need to carry paper books and you can search for key terms. In this issue you will find: Good Clinical Practice For Your Reference - Book 5 ICH - Efficacy Guidelines E3 – E15 ICH-E3: Clinical Study Reports ICH-E3 - Structure and Content of Clinical Study Reports ICH-E4: Dose-Response Information to Support Drug Registration ICH-E5: Ethnic Factors in the Acceptability of foreign Clinical Data ICH-E6: Guideline for Good Clinical Practice ICH-E7: Studies in Support of Special Populations: Geriatrics ICH-E8: General Considerations for Clinical Trials ICH-E9: Statistical Principles for Clinical Trials ICH E-10: Choice of Control Group and Related Issues in Clinical Trials ICH-E11: Clinical Investigation of Medicinal Products in the Pediatric Population ICH-E12: Draft ICH Consensus Principle Principles for Clinical Evaluation of New Antihypertensive Drugs ICH-E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs ICH-E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories

Author: Joel Morganroth
Publisher:
ISBN: 9789024723362
Category : Arrhythmia
Languages : en
Pages :

View

Book Description

Author: United States. Food and Drug Administration
Publisher:
ISBN:
Category : Antidiarrheals
Languages : en
Pages : 24

View

Book Description